Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies

Until now, a disease-modifying therapy (DMT) that has an ability to slow or arrest Alzheimer's disease (AD) progression has not been developed, and all clinical trials involving AD patients enrolled by clinical assessment alone also have not been successful. Given the growing consensus that the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Korean J Physiol Pharmacol
Autors principals: Kang, Ju-Hee, Ryoo, Na-Young, Shin, Dong Wun, Trojanowski, John Q, Shaw, Leslie M.
Format: Artigo
Idioma:Inglês
Publicat: The Korean Physiological Society and The Korean Society of Pharmacology 2014
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296032/
https://ncbi.nlm.nih.gov/pubmed/25598657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4196/kjpp.2014.18.6.447
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars